SCHEMBL4471193

SCHEMBL4471193

Clc1ccc(COC2CCNCC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.58
SLC6A2 P23975 6/20 0.58
SLC6A3 Q01959 6/20 0.58
HTR2C P28335 2/20 0.58
HTR2B P41595 2/20 0.58
HTR2A P28223 1/20 0.58
HTR7 P34969 1/20 0.58
HTR3A P46098 1/20 0.58
HTR4 Q13639 1/20 0.58
CARM1 Q86X55 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
REN P00797 2/20 0.49
KCNH2 Q12809 4/20 0.48
HTR6 P50406 1/20 0.47
HRH1 P35367 2/20 0.43
IDO1 P14902 2/20 0.42
AGXT P21549 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19921391 0.98 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL654966 0.90 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL654491 0.90 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL654490 0.90 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
Hydrochloric Acid SCHEMBL5811325 0.88 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL18616158 0.83 CARM1 (0.55) SLC6A4SLC6A2SLC6A3CARM1PRMT6
SCHEMBL5543056 0.83 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL16771160 0.82 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL7159318 0.82 SLC6A2 (0.58) SLC6A4SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL18380998 0.82 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689650-B Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole 阿克萨姆股份公司 2022-11-25 CN disclosed
EP-3507287-B1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM SPA (IT) 2020-07-15 EP disclosed
EP-3507287-B1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM SPA (IT) 2020-07-15 EP disclosed
US-10669267-B2 Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists AXXAM S.P.A. (IT) 2020-06-02 US disclosed
US-10669267-B2 Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists AXXAM S.P.A. (IT) 2020-06-02 US disclosed
EP-3507287-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM S.p.A. (IT) 2019-07-10 EP disclosed
US-20190194180-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM S.P.A. (IT) 2019-06-27 US disclosed
US-20190194180-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM S.P.A. (IT) 2019-06-27 US disclosed
WO-2018041563-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS AXXAM S.P.A. (IT) 2018-03-08 WO disclosed
EP-3290416-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR ANTAGONIST AXXAM S.p.A. (IT) 2018-03-07 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20070185101-A1 Antiparasitic terpene alkaloids PFIZER PRODUCTS INC 2007-08-09 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-1328514-A1 AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2003-07-23 EP disclosed
WO-2002034718-A1 AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194180-A1 SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS P2RX7, P2RX2, P2RX1 SLC6A4 907/4885SLC6A2 1033/4885SLC6A3 1564/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC6A4 4191/4885SLC6A2 3396/4885SLC6A3 1944/4885
US-10669267-B2 Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists P2RX7, P2RX2, P2RX1 SLC6A4 907/4885SLC6A2 1033/4885SLC6A3 1564/4885
US-20070185101-A1 Antiparasitic terpene alkaloids CYP51A1, DHPS, CYP8B1 SLC6A4 2221/4885SLC6A2 1939/4885SLC6A3 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.